Literature DB >> 1325035

Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs.

B J Pereira1, E L Milford, R L Kirkman, S Quan, K R Sayre, P J Johnson, J C Wilber, A S Levey.   

Abstract

BACKGROUND: There is a high prevalence of liver disease among the recipients of organs from donors with antibodies to hepatitis C virus (HCV). We undertook a study to determine the frequency of persistent HCV infection, as indicated by the presence of HCV RNA, among both cadaveric organ donors positive for antibodies to HCV (anti-HCV) and the recipients or organs from these donors.
METHODS: Serum samples from donors and recipients were tested for HCV RNA with the reverse transcriptase polymerase chain reaction, with use of primers from the 5' untranslated region of the HCV genome, and for anti-HCV with the first-generation enzyme-linked immunosorbent assay (ELISA) and two second-generation tests.
RESULTS: HCV RNA was detected in 9 of the 11 organ donors (82 percent) with a positive first-generation ELISA for anti-HCV. Among the organ recipients, the prevalence of HCV RNA increased after transplantation: 7 of 26 patients (27 percent) had positive samples before transplantation, as compared with 23 of 24 patients (96 percent) after transplantation (P less than 0.001). Among 13 recipients who were HCV RNA-negative before receiving organs from the nine HCV RNA-positive donors, HCV infection was detected in all 13 after transplantation, and anti-HCV developed in 8 (62 percent). On the basis of a positive test for HCV RNA, the maximal sensitivity of the three anti-HCV tests was 57 percent (positive in 4 of 7 patients with end-stage organ failure) before transplantation and 70 percent (positive in 16 of 23 patients) after transplantation.
CONCLUSIONS: Nearly all the recipients of organs from anti-HCV-positive donors become infected with HCV. The current tests for anti-HCV antibodies underestimate the incidence of transmission and the prevalence of HCV infection among immunosuppressed organ recipients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325035     DOI: 10.1056/NEJM199209243271302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Mohammad A B Al-Freah; Zeino Zeino; Michael A Heneghan
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis. The EATHIS Eco Research Group. European Acute Transfusion Hepatitis Interferon Study.

Authors:  C Colin; P Vergnon; A M Jullien; S Excoffier; Y Matillon; C Trepo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

3.  Hepatitis C: Recent advances.

Authors:  S D Shafran; J M Conly
Journal:  Can J Infect Dis       Date:  1993-07

4.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

5.  Transplant-associated autoimmune mechanisms in human hepatitis C virus infection.

Authors:  K Zucker; D Roth; R Cirocco; J Mathew; M Carreno; L Fuller; T Karatzas; Y Jin; G Burke; J Nery; M Webb; A Tzakis; V Esquenazi; J Miller
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

6.  Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation.

Authors:  M Pastore; M Willems; C Cornu; J P Buts; R Reding; J de Ville de Goyet; J Rahier; J B Otte; S H Yap; E M Sokal
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

Review 7.  Quality of life after orthotopic liver transplantation in children. An overview of physical, psychological and social outcome.

Authors:  E M Sokal
Journal:  Eur J Pediatr       Date:  1995-03       Impact factor: 3.183

8.  Incidence and morbidity of infection by hepatitis C virus in children with acute lymphoblastic leukaemia.

Authors:  S P Dibenedetto; R Ragusa; A Sciacca; A Di Cataldo; V Miraglia; S D'Amico; L Lo Nigro; A M Ippolito
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

9.  Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease.

Authors:  W H Grotz; T H Peters; H J Schlayer; G Kirste; H Berthold; H Felten; P J Schollmeyer; J W Rasenack
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

Review 10.  Treatment of hepatitis C in solid organ transplantation.

Authors:  Susan E Chan; Jonathan M Schwartz; Hugo R Rosen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.